Clicky

Aerovate Therapeutics, Inc.(AVTE)

Description: Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's initial focus is on advancing AV-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or PAH.


Keywords: Medicine Clinical Medicine Chemical Compounds Hypertension Pulmonary Arterial Hypertension Orphan Drug Pulmonary Hypertension Piperazines Imatinib

Home Page: aerovatetx.com

AVTE Technical Analysis

930 Winter Street
Waltham, MA 02116
United States
Phone: 617 443 2400


Officers

Name Title
Mr. Timothy P. Noyes M.B.A. CEO & Director
Dr. Benjamin T. Dake Ph.D. Founder, Pres, COO & Sec.
Mr. George A. Eldridge CFO & Treasurer
Mr. Hunter Gillies M.D. Chief Medical Officer
Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S Chief Scientific Officer
Mr. Timothy J. Pigot Sr. VP of Commercial
Ms. Donna Dea Head of Regulatory Affairs
Dr. Marinus Verwijs Ph.D. Sr. VP of CMC
Ms. Susan Fischer Sr. VP of Devel. Operations
Mr. Stephen Yu Sr. VP of Quality

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0.8598
Price-to-Book MRQ: 4.5483
Price-to-Sales TTM: 0
IPO Date: 2021-06-30
Fiscal Year End: December
Full Time Employees: 33
Back to stocks